| Apolipoproteins as markers and managers of coronary risk. | |
| | |
MedLine Citation:
|
PMID: 16504986 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Coronary artery disease (CAD) is a major cause of morbidity and mortality in Western communities. Reliable indices of coronary risk assessment and targets for drug treatment are important to the management of patients. Although plasma LDL cholesterol is well established as a predictor of CAD, it may not be the best circulatory marker. Results from recent epidemiological studies and statin trials suggest that apolipoprotein B-100 (apoB), with or without apoA-I, is superior to LDL cholesterol in predicting coronary events. Measurements of apolipoproteins are internationally standardized, automated, cost-effective and more convenient and precise than those for LDL cholesterol. ApoB may also be preferable to the measurement of non-HDL cholesterol. Measurement of apolipoproteins (apoB and possibly apoA-I) should be routinely added to the routine lipid profile (cholesterol, triglycerides and high-density lipoprotein cholesterol) to assess the atherogenic potential of lipid disorders. This is particularly relevant to dyslipidaemias characterized by an elevation in plasma triglycerides. Apolipoproteins, especially apoB, could also replace the standard "lipid profile" as a target for therapy in at-risk patients. |
| | |
Authors:
|
D C Chan; G F Watts |
Related Documents
:
|
18548846 - Kale juice improves coronary artery disease risk factors in hypercholesterolemic men. 1286136 - Triglyceride, high density lipoprotein, and coronary heart disease. 3904336 - The effects of trimazosin and pindolol on serum lipids, blood glucose and serum insulin... 8746876 - Perimenopausal changes in serum lipids and lipoproteins: a 7-year longitudinal study. 11134986 - Fat distribution: a morphologic study of the aging face. 15313486 - Osmoregulatory response to acute diet change in an avian nectarivore: rapid rehydration... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2006-02-27 |
Journal Detail:
|
Title: QJM : monthly journal of the Association of Physicians Volume: 99 ISSN: 1460-2725 ISO Abbreviation: QJM Publication Date: 2006 May |
Date Detail:
|
Created Date: 2006-04-26 Completed Date: 2006-11-02 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9438285 Medline TA: QJM Country: England |
Other Details:
|
Languages: eng Pagination: 277-87 Citation Subset: IM |
Affiliation:
|
School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, GPO Box X2213, Perth, WA 6847, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
therapeutic use Apolipoprotein A-I / blood Apolipoprotein B-100 Apolipoproteins / blood* Apolipoproteins B / blood Biological Markers / blood Cholesterol / blood* Cholesterol, HDL / blood Cholesterol, LDL / blood Coronary Artery Disease / blood, diagnosis*, drug therapy Female Humans Male Risk Assessment |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Apolipoprotein A-I; 0/Apolipoprotein B-100; 0/Apolipoproteins; 0/Apolipoproteins B; 0/Biological Markers; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 57-88-5/Cholesterol |
| Comments/Corrections | |
Erratum In:
|
QJM. 2006 Nov;99(11):807 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prognostic value of admission glucose and glycosylated haemoglobin levels in acute coronary syndrome...
Next Document: Cryptococcosis in apparently immunocompetent patients.